Literature DB >> 21506426

[Pharmacokinetics of triptolide in Triptergium wilfordii microemulsion gel].

Yongmei Guan1, Zhihong Yan, Lihua Chen, Weifeng Zhu, Ming Yang.   

Abstract

OBJECTIVE: To establish a method of determinating the plasma concentration about the triptolide in rat in vivo. And to study the pharmacokinetics of triptolide in transdermal drug delivery system of Triptergium wilfordii microemulsion gel.
METHOD: The T. wilfordii tablet was regarded as the control, the plasma concentration of triptolide was determined by LC-MS/MS after different route of administration, and the pharmacokinetic parameters were calculated by DAS. RESULT: The linear relation of triptolide was excellent within the range of 1-200 ng (r = 0.9967). The minimum detectable concentration were 0.5 microg x L(-1). It was the first-order process. And the pharmacokinetic parameters of triptolide in microemulsion gel was as follow: t(1/2) (2.4 +/- 3.00) h,tmax (6.7 +/- 1.63) h, Cmax (82.9 +/- 17.63) microg x L(-1). To compare the tablets, the microemulsion gel has a longer peak time, and maintain a longer stable plasma concentration. The AUC of tablets and microemulsion gel were (2595.3 +/- 551.15) h x microg x L(-1) and (209.9 +/- 25.34) h x microg x L(-1) and it was a significant differences between the tablet and microemulsion gel (P < 0. 01).
CONCLUSION: T. wilfordii has rapid absorption in rat in vivo and a stable and persistent plasma concentration after transdermal drug delivery. Therefore, it is rationality after transdermal drug delivery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506426

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Pharmacokinetics and Tissue Distribution of Combined Triptolide and Paeoniflorin Regimen for Percutaneous Administration in Rats Assessed by Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Yong-Mei Guan; Qian Shen; Liang-Fei He; Li-Mei Chen; Zhenzhong Zang; Lili Liu; Wei-Feng Zhu; Chen Li-Hua; Hong-Ning Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-08       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.